2017 News Releases

Webcast ImageWebcast
Clovis Oncology’s Rucaparib Significantly Improved Progression-Free Survival in All Ovarian Cancer Patient Populations Studied in Phase 3 ARIEL3 Maintenance Treatment Trial (Replay)
06/19/17 at 8:30 a.m. ET
Clovis Oncology’s Rucaparib Significantly Improved Progression-Free Survival in All Ovarian Cancer Patient Populations Studied in Phase 3 ARIEL3 Maintenance Treatment Trial
Monday, June 19, 2017 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
06/21/17Clovis Oncology Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock
BOULDER, Colo.--(BUSINESS WIRE)--Jun. 21, 2017-- Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the underwriters of its recently announced public offering of its common stock have exercised in full their option to purchase an additional 511,363 shares. The offering, including the sale of the additional shares, is expected to close on June 26, 2017, subject to customary closing conditions. Clovis Oncology intends to use th... 
Printer Friendly VersionDownload PDF
06/20/17Clovis Oncology Announces Upsizing and Pricing of Public Offering of Common Stock
BOULDER, Colo.--(BUSINESS WIRE)--Jun. 20, 2017-- Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of an underwritten public offering of 3,409,091 shares of its common stock at $88.00 per share, before underwriting discounts and commissions. The size of the offering was upsized from $250 million to $300 million. In addition, the underwriters have a 30-day option to purchase up to an additional 511,363 shares of common stock from Clovis Onco... 
Printer Friendly VersionDownload PDF
06/19/17Clovis Oncology Announces Proposed Offering of Common Stock
BOULDER, Colo.--(BUSINESS WIRE)--Jun. 19, 2017-- Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $250 million. All shares of the common stock to be sold in the offering will be offered by Clovis Oncology. Clovis Oncology intends to use the net proceeds of the offering for general corporate purposes, including... 
Printer Friendly VersionDownload PDF
06/19/17Clovis Oncology’s Rucaparib Significantly Improved Progression-Free Survival in All Ovarian Cancer Patient Populations Studied in Phase 3 ARIEL3 Maintenance Treatment Trial
The ARIEL3 study successfully achieved its primary endpoint of improved PFS by investigator review in all three primary efficacy analyses: tumor BRCA-mutant, HRD-positive and overall intent-to-treat populations The ARIEL3 study successfully achieved the key secondary endpoint of improved PFS by blinded, independent central review (BICR) in each of the tumor BRCA-mutant, HRD-positive and overall intent-to-treat populat... 
Printer Friendly VersionDownload PDF
05/23/17Clovis Oncology Announces Presentations at 2017 ASCO Annual Meeting
Updates on rucaparib clinical trials in multiple solid tumors and therapy settings at ASCO Annual Meeting; top-line data from ARIEL3 pivotal study anticipated by end of June BOULDER, Colo.--(BUSINESS WIRE)--May 23, 2017-- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that abstracts highlighting progress in the rucaparib clinical development program will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting... 
Printer Friendly VersionDownload PDF
05/03/17Clovis Oncology Announces First Quarter 2017 Operating Results
Strong Q1 launch quarter for Rubraca® (rucaparib) in U.S. with $7M reported in net sales Clovis notified that ARIEL3 target progression events achieved in mid-April Top-line ARIEL3 data anticipated by end of June Multiple clinical trials initiated in early 2017, including TRITON2 and TRITON3 in prostate cancer and Roche-sponsored rucaparib-atezolizumab combination study in gynecologic c... 
Printer Friendly VersionDownload PDF
04/27/17Myriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx® Test to Identify Patients with Germline BRCA Mutations for Rubraca® (rucaparib) Treatment
SALT LAKE CITY, Utah & BOULDER, Colo., April 27, 2017 – Myriad Genetics, Inc. (NASDAQ: MYGN) and Clovis Oncology, Inc. (NASDAQ:CLVS) today announced a companion diagnostic collaboration to support a post-marketing regulatory commitment related to Clovis' PARP inhibitor, Rubraca.  Financial terms of the deal were not disclosed.Under the agreement, Myriad will submit a supplementary premarket approval (sPMA) application under its existing PMA for BRACAnalysis CDx to include Rubraca.  The... 
Printer Friendly VersionDownload PDF
04/20/17Clovis Oncology to Announce First Quarter 2017 Financial Results and Host Webcast Conference Call on May 3
BOULDER, Colo.--(BUSINESS WIRE)--Apr. 20, 2017-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2017 financial results on Wednesday, May 3, 2017, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the company’s results in greater detail. The conference call is being webcast and can be accessed from the Clovis O... 
Printer Friendly VersionDownload PDF
03/28/17Clovis Oncology Announces Data Presentations at AACR Annual Meeting 2017
Abstracts provide new insights into rucaparib’s mechanism of action and function in multiple disease and therapy settings FDA approved Rubraca® (rucaparib) tablets in late 2016 as monotherapy treatment for women with BRCA-mutated advanced ovarian cancer BOULDER, Colo.--(BUSINESS WIRE)--Mar. 28, 2017-- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that rucaparib preclinical data will be presented at the Am... 
Printer Friendly VersionDownload PDF
03/12/17Clovis Oncology Presents New Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer at 2017 SGO Annual Meeting on Women’s Cancer
New rucaparib data presented today in two oral plenary sessions Data provide additional insights from ARIEL2 Phase 2 study of rucaparib in advanced ovarian cancer FDA approved Rubraca® (rucaparib) tablets in December 2016 as monotherapy treatment for women with BRCA-mutated advanced ovarian cancer based on data from Study 10 and ARIEL2 BOULDER, Colo.--(BUSINESS WIRE)--Mar. 12, 2017-- Clovis Onc... 
Printer Friendly VersionDownload PDF
02/22/17Clovis Oncology Announces 2016 Operating Results
Rubraca™ (rucaparib) approved and launched in the U.S. on December 19, 2016 for the treatment of advanced BRCA-mutant ovarian cancer $266.2M in cash, cash equivalents and available for sale securities at December 31, 2016 $487.4M in adjusted cash, cash equivalents and available for sale securities at December 31, 2016 as adjusted for the January 2017 financing proceeds of $221.2 million ... 
Printer Friendly VersionDownload PDF
02/09/17Clovis Oncology to Announce Fourth Quarter/Year-End 2016 Financial Results and Host Webcast Conference Call on February 22
BOULDER, Colo.--(BUSINESS WIRE)--Feb. 9, 2017-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter/year-end 2016 financial results on Wednesday, February 22, 2017, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the company’s results in greater detail. The conference call is being webcast and can be accessed from the ... 
Printer Friendly VersionDownload PDF
02/01/17Clovis Oncology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Rucaparib Prostate Cancer Development Program
Strata Trial to Identify Genetically Selected Patients Eligible for Enrollment in Clovis’ TRITON Studies in Advanced Prostate Cancer BOULDER, Colo. & ANN ARBOR, Mich.--(BUSINESS WIRE)--Feb. 1, 2017-- Clovis Oncology, Inc. (NASDAQ: CLVS) and Strata Oncology, Inc. today announced an agreement to accelerate patient identification and enrollment for Clovis’ ongoing TRITON (Trial of Rucaparib in Prostate Indications) clinical trial program, which includes... 
Printer Friendly VersionDownload PDF
01/09/17Clovis Oncology to Present at the 35th Annual J.P. Morgan Healthcare Conference
BOULDER, Colo.--(BUSINESS WIRE)--Jan. 9, 2017-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017 at 2:30 PM Pacific Time. The conference will be held at the Westin St. Francis Hotel in San Francisco. A live webcast of the presentation and breakout session can be accessed thro... 
Printer Friendly VersionDownload PDF
01/04/17Clovis Oncology Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock
BOULDER, Colo.--(BUSINESS WIRE)--Jan. 4, 2017-- Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the underwriters of its recently announced public offering of its common stock have exercised in full their option to purchase an additional 750,000 shares. The offering, including the sale of the additional shares, is expected to close on January 9, 2017, subject to customary closing conditions. Clovis Oncology intends to use t... 
Printer Friendly VersionDownload PDF
01/03/17Clovis Oncology Announces Upsizing and Pricing of Public Offering of Common Stock
BOULDER, Colo.--(BUSINESS WIRE)--Jan. 3, 2017-- Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at $41.00 per share, before underwriting discounts and commissions. The size of the offering was upsized from $175 million to $205 million. In addition, the underwriters have a 30-day option to purchase up to an additional 750,000 shares of common stock from Clovis Oncol... 
Printer Friendly VersionDownload PDF
01/03/17Clovis Oncology Announces Proposed Offering of Common Stock
BOULDER, Colo.--(BUSINESS WIRE)--Jan. 3, 2017-- Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $175 million. All shares of the common stock to be sold in the offering will be offered by Clovis Oncology. Clovis Oncology intends to use the net proceeds of the offering for general corporate purposes, including ... 
Printer Friendly VersionDownload PDF
Investor Relations and Corporate Communications Contacts
Breanna Burkart
Phone: 303.625.5023
E-mail: bburkart@clovisoncology.com
Anna Sussman
Phone: 303.625.5022
E-mail: asussman@clovisoncology.com